US Approves Experimental Ebola Treatment Amid Kenya Quarantine Concerns

The U.S. government has approved an experimental Ebola antibody treatment for individuals with high-risk exposure, as concerns mount over containment plans related to a proposed quarantine facility in Kenya. The Department of Health and Human Services (HHS) confirmed that Americans exposed to Ebola in the ongoing Central Africa outbreak will be eligible for the investigational therapy, called MBP-134. The antibody treatment, developed by Mapp Biopharmaceuticals in the U.S., has demonstrated promising results in animal studies but has not yet completed full clinical trials in humans, according to StatNews. Health officials stated the therapy will be administered under emergency investigational use mechanisms permitted by the Food and Drug Administration for unapproved medical treatments during outbreaks. The decision comes as the U.S. government continues to coordinate response efforts for Ebola cases linked to the outbreak in the Democratic Republic of Congo and neighboring Uganda. Although the treatment remains in limited supply, authorities have not disclosed the exact number of available doses, citing ownership and distribution arrangements under the Biomedical Advanced Research and Development Authority (BARDA). Simultaneously, the U.S. has encountered increasing scrutiny over its plan to establish a 50-bed bio-isolation and quarantine facility in Laikipia County for exposed individuals. The facility has faced resistance from residents who have raised concerns about safety, transparency, and the decision to host such a center in Kenya. Kenyan authorities and U.S. officials, however, maintain that the facility is designed to prevent disease spread and enhance regional capacity to detect and isolate potential cases. The U.S. Embassy in Nairobi has insisted that the quarantine center poses no risk to surrounding communities, describing it as part of a broader strategy. The embassy also stated that Washington has committed more than Ksh20 billion in direct support for Ebola response efforts in Africa, with additional funding channeled through international humanitarian mechanisms. Despite these assurances, the planned facility has triggered political and public backlash, with protests reported in Laikipia in recent days over perceived health and security risks. Meanwhile, health experts note that the experimental antibody therapy, MBP-134, could be a breakthrough treatment if proven effective in humans, highlighting that outbreaks provide critical opportunities for real-world clinical trials.